Targeting SALL4 by entinostat in lung cancer
Yong, Kol Jia
Hong, Clarice Kit Yee
MetadataShow full item record
CitationYong, K. J., A. Li, W. Ou, C. K. Y. Hong, W. Zhao, F. Wang, H. Tatetsu, et al. 2016. “Targeting SALL4 by entinostat in lung cancer.” Oncotarget 7 (46): 75425-75440. doi:10.18632/oncotarget.12251. http://dx.doi.org/10.18632/oncotarget.12251.
AbstractThe overall survival of lung cancer patients remains dismal despite the availability of targeted therapies. Oncofetal protein SALL4 is a novel cancer target. We herein report that SALL4 was aberrantly expressed in a subset of lung cancer patients with poor survival. SALL4 silencing by RNA interference or SALL4 peptide inhibitor treatment led to impaired lung cancer cell growth. Expression profiling of SALL4-knockdown cells demonstrated that both the EGFR and IGF1R signaling pathways were affected. Connectivity Map analysis revealed the HDAC inhibitor entinostat as a potential drug in treating SALL4-expressing cancers, and this was confirmed in 17 lung cancer cell lines. In summary, we report for the first time that entinostat can target SALL4-positive lung cancer. This lays the foundation for future clinical studies evaluating the therapeutic efficacy of entinostat in SALL4-positive lung cancer patients.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:32072105
- HMS Scholarly Articles